09.12.2014 - Belgian Ablynx NV welcomed Johan Heylen as its new Chief Commercial Officer. The Flemish drug developer announced the cast in mid-November.
Heylen will assume responsibility for all commercial activities. Having more than 20 years of experience in global biopharmaceutical sales, marketing and business development at GlaxoSmithKline (GSK), Servier and Wyeth, he most recently was Executive Director, Global Commercial Lead, Cancer Immunotherapeutics, at pharma heavyweight GSK. At GSK, Heylen was responsible for the development and implementation of the launch strategy for GSK’s cancer immunotherapeutics portfolio. Prior to that, Heylen led and launched the successful global commercial and marketing efforts for three of GSK’s paediatric vaccines, Rotarix, Priorix and Varilrix, which together achieved sales of more than €1.5bn. "He will also bring valuable expertise to our business development team as we seek to develop our relationships with pharmaceutical companies around the world,” expects Edwin Moses, CEO of Ablynx.
With Heylen at the steering wheel, Ablynx is now ready to board the market with its nanobodies. This summer, the antibody specialist managed to raise €41.7m through a private placement of new shares.http://www.european-biotechnology-news.com/people/bio-people/2014/johan-heylen.html